This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
27 Aug 2020

Press Release > CordenPharma Increases US Peptide Manufacturing Capacity to Accommodate Global Market Growth

Large-scale Peptide Manufacturing Expansion in CordenPharma Colorado (US).

Luxembourg, 7 July 2020 - CordenPharma is proud to announce peptide manufacturing capacity expansion in CordenPharma Colorado, their GMP API facility in Boulder, CO (US). Already known for its unique large-scale peptide offering with a 10’000 L SPPS (Solid-Phase Peptide Synthesis) vessel, and a 100 cm high-pressure reverse phase purification column, CordenPharma Colorado is recognized as the largest worldwide peptide API producer leading the global peptide market.

In order to accommodate a large spike in the demand for peptide APIs, and to continue an overall growth strategy, CordenPharma Colorado recently completed expansion of their solid-phase peptide manufacturing capacity. Dr. Matthieu Giraud, Director, Global Peptides, Lipids & Carbohydrates Platform, explains: “With the addition of this extra-large 3’000 L SPPS vessel, our assembly-time, capacity and flexibility has been significantly increased, reinforcing CordenPharma Colorado as the current large-scale peptide manufacturing capacity leader. This new asset gives us the ability to manufacture a complex long peptide with a 400 kg output per single batch. Our team in Colorado aims to utilize this new capacity to conduct validation campaigns designed to support customer projects with a global impact.”

CordenPharma has over 130 years of cumulative experience across its global facility network in the US & Europe, which allows for a high-level of response to growing local demand at the country and community level, particularly during the recent COVID-19 pandemic.

With approximately 300 employees, CordenPharma Colorado has grown a strong focus in the development & manufacturing of APIs from laboratory-scale to commercialization at ton-scale, due to their unique large-scale SPPS capabilities. The purification of the final peptide is performed at any scale in columns ranging from 5 cm to 100 cm. To avoid the tedious and poor productivity of the final isolation step by lypohilization, their development team gained an unmatched expertise in peptide precipitation that successfully transferred to production in commercial products. The site has a long track record in large-scale manufacturing, where all potencies, including picogram levels, can be reached.

Mentioned Companies
Corden Pharma International GmbH
View company profile